Single cell resolution in vivo imaging of DNA damage following PARP inhibition
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Single cell resolution in vivo imaging of DNA damage following PARP inhibition
Authors
Keywords
-
Journal
Scientific Reports
Volume 5, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-05-18
DOI
10.1038/srep10129
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Imaging Therapeutic PARP Inhibition In Vivo through Bioorthogonally Developed Companion Imaging Agents
- (2015) Thomas Reiner et al. NEOPLASIA
- Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
- (2014) Eiji Kubota et al. CELL CYCLE
- New Insights into PARP Inhibitors' Effect on Cell Cycle and Homology-Directed DNA Damage Repair
- (2014) P. Jelinic et al. MOLECULAR CANCER THERAPEUTICS
- PARP inhibitors bounce back
- (2013) Ken Garber NATURE REVIEWS DRUG DISCOVERY
- Double-strand break repair: 53BP1 comes into focus
- (2013) Stephanie Panier et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo
- (2013) Greg M. Thurber et al. Nature Communications
- Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
- (2012) A. G. Patel et al. CLINICAL CANCER RESEARCH
- Quantitative Live Cell Imaging Reveals a Gradual Shift between DNA Repair Mechanisms and a Maximal Use of HR in Mid S Phase
- (2012) Ketki Karanam et al. MOLECULAR CELL
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
- (2012) Bryan A. Gibson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of Mitosis and Antimitotic Drug Responses in Tumors by In Vivo Microscopy and Single-Cell Pharmacodynamics
- (2011) J. D. Orth et al. CANCER RESEARCH
- Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent
- (2011) Diana Nguyen et al. CELL CYCLE
- Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer
- (2011) Stan B. Kaye et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Re-evaluating PARP1 inhibitor in cancer
- (2011) Alexei Tulin NATURE BIOTECHNOLOGY
- PARP inhibitors stumble in breast cancer
- (2011) Malini Guha NATURE BIOTECHNOLOGY
- 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress
- (2011) Claudia Lukas et al. NATURE CELL BIOLOGY
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
- (2010) U. Kortmann et al. CLINICAL CANCER RESEARCH
- Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer
- (2010) C. M. Annunziata et al. CLINICAL CANCER RESEARCH
- How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation
- (2010) Aswin Mangerich et al. INTERNATIONAL JOURNAL OF CANCER
- Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
- (2010) Yvette Drew et al. JNCI-Journal of the National Cancer Institute
- New functions for an ancient domain
- (2009) W Lee Kraus NATURE STRUCTURAL & MOLECULAR BIOLOGY
- A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation
- (2009) Gyula Timinszky et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler
- (2009) A. J. Gottschalk et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Poly(ADP-ribose)-Dependent Regulation of DNA Repair by the Chromatin Remodeling Enzyme ALC1
- (2009) D. Ahel et al. SCIENCE
- Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
- (2008) B. Evers et al. CLINICAL CANCER RESEARCH
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
- An Oligomerized 53BP1 Tudor Domain Suffices for Recognition of DNA Double-Strand Breaks
- (2008) O. Zgheib et al. MOLECULAR AND CELLULAR BIOLOGY
- 53BP1 promotes non-homologous end joining of telomeres by increasing chromatin mobility
- (2008) Nadya Dimitrova et al. NATURE
- Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes
- (2008) Jean-Philippe Gagné et al. NUCLEIC ACIDS RESEARCH
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now